It's my understanding that we have only seven chief negotiators, and I agree with you that if we have a limited number of chief negotiators, going into these different trade deals might be problematic for the government.
Professor Hart, I have a question for you. You talked about the intellectual property rights and the interests of pharmaceutical companies in the States and in Europe. Knowing what you know of some of the trade agreements that are being negotiated, what impact would that have on drug costs in Canada?